AMPYRA Drug Patent Profile

When do Ampyra patents expire, and when can generic versions of Ampyra launch?

Ampyra is a drug marketed by Merz and is included in one NDA.

The generic ingredient in AMPYRA is dalfampridine. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dalfampridine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ampyra

A generic version of AMPYRA was approved as dalfampridine by ACTAVIS LABS FL INC on January 23^rd, 2017.

Summary for AMPYRA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	22
Patent Applications:	3,681
Drug Prices:	Drug price information for AMPYRA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMPYRA
What excipients (inactive ingredients) are in AMPYRA?	AMPYRA excipients list
DailyMed Link:	AMPYRA at DailyMed

See drug prices for AMPYRA

Recent Clinical Trials for AMPYRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
John Elfar	PHASE2
MGH Institute of Health Professions	Phase 4
Milton S. Hershey Medical Center	Phase 2/Phase 3

See all AMPYRA clinical trials

Pharmacology for AMPYRA

Drug Class	Potassium Channel Blocker
Mechanism of Action	Potassium Channel Antagonists

Paragraph IV (Patent) Challenges for AMPYRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMPYRA	Extended-release Tablets	dalfampridine	10 mg	022250	8	2014-01-22

US Patents and Regulatory Information for AMPYRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	AB	RX	Yes	Yes

Expired US Patents for AMPYRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	8,440,703
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	5,370,879
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	8,663,685
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	9,918,973
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	5,540,938

International Patents for AMPYRA

See the table below for patents covering AMPYRA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5736100
Slovenia	1732548
European Patent Office	2422782	Utilisation de compositions d'aminopyridine à libération soutenue (Methods of Using Sustained Release Aminopyridine Compositions)
Croatia	P20110497
South Africa	9108711

Supplementary Protection Certificates for AMPYRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1732548	PA2012001,C1732548	Lithuania		PRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
2377536	122013000046	Germany		PRODUCT NAME: 4-AMINOPYRIDIN ODER EIN DERIVAT DAVON, INSBESONDERE EIN SALZ, EIN SOLVAT ODER EINE PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
2377536	25/2013	Austria		PRODUCT NAME: 4-AMINOPYRIDIN ODER DESSEN SALZE; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
2377536	C 2013 021	Romania		PRODUCT NAME: FAMPRIDINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/699/001-002; DATE OF NATIONAL AUTHORISATION: 20110720; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/699/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20110720
2377536	132013902176892	Italy		PRODUCT NAME: FAMPRIDINA(FAMPYRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/699/001-002, 20110720

Ampyra: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Ampyra (dalfampridine) is a potassium channel blocker approved to improve walking in adults with multiple sclerosis (MS). Its market trajectory has been shaped by patent expirations, generic competition, and ongoing clinical applications.

What is the current market position of Ampyra?

Ampyra's market position has transitioned from a novel therapeutic to a product facing significant generic competition. Originally developed by Elan Pharmaceuticals and later Acorda Therapeutics, the drug received FDA approval in January 2010 for symptomatic improvement of walking in MS patients.

Key market events include:

• Initial Launch and Growth: Ampyra captured a significant share of the MS market due to its unique mechanism of action and demonstrated efficacy in improving walking speed, a critical symptom for MS patients. Sales peaked in the years preceding patent expiry.
• Patent Expirations and Litigation: The primary patents covering Ampyra expired in 2017, leading to the introduction of generic versions. Acorda Therapeutics engaged in patent litigation to defend its market exclusivity, but ultimately lost key challenges. For instance, in December 2018, the U.S. Court of Appeals for the Federal Circuit upheld a ruling invalidating a key patent on Ampyra, paving the way for generic entry.
• Generic Entry and Market Share Erosion: Following the patent challenges, multiple generic manufacturers launched dalfampridine extended-release tablets. This resulted in a rapid decline in Ampyra's market share and a significant decrease in its pricing power.
• Current Market Status: Ampyra (brand name) now represents a small fraction of the dalfampridine market. Generic dalfampridine is widely available and prescribed, offering a lower-cost alternative for patients and payers.

What are the key financial performance indicators for Ampyra and its generics?

The financial performance of Ampyra has been characterized by substantial revenue generation during its exclusivity period, followed by a sharp decline post-generic entry.

Ampyra (Brand Name) Revenue (Acorda Therapeutics)

Year	Net Revenue (Millions USD)	Notes
2016	$590.2	Peak revenue year prior to significant patent challenges.
2017	$585.8	Continued strong performance, but patent challenges began impacting outlook.
2018	$533.2	First full year of significant generic competition following patent rulings.
2019	$384.5	Continued erosion of brand revenue.
2020	$248.0	Further decline as generics dominate.
2021	$144.5	Substantial reduction in brand revenue.
2022	$76.3	Minimal revenue contribution from the branded product.
2023 (Est.)	~$50-60 (projected)	Continued decline of branded sales.

Source: Acorda Therapeutics Annual Reports and SEC Filings [1, 2]. Estimates for 2023 are based on trends and market analysis.

Generic Dalfampridine Market Dynamics:

• Price Compression: Generic competition has led to significant price reductions. The average selling price for generic dalfampridine is estimated to be 70-90% lower than the brand-name Ampyra at its peak.
• Market Volume: While the unit volume of dalfampridine prescriptions has remained relatively stable or seen modest growth due to wider accessibility and lower cost, the overall market value has decreased substantially due to price compression.
• Manufacturer Landscape: Multiple generic manufacturers, including Teva Pharmaceuticals, Mylan (now Viatris), and Accord Healthcare, produce and market generic dalfampridine. This competitive landscape further drives down prices.
• Reimbursement: Payers generally favor generic dalfampridine due to its cost-effectiveness, leading to formulary preference and increased generic utilization.

What are the patent and regulatory hurdles impacting Ampyra's market exclusivity?

The patent and regulatory landscape has been the primary driver of Ampyra's market exclusivity challenges.

Key Patents and Expirations:

• U.S. Patent No. 6,936,277: This patent, covering a method of treating MS by administering dalfampridine, was a cornerstone of Acorda's market exclusivity. It was initially set to expire in 2021 but became subject to invalidation challenges.
• U.S. Patent No. 7,855,208: This patent was also central to Ampyra's protection.
• Patent Invalidation Rulings: Acorda faced numerous patent litigations. In a significant ruling in December 2018, the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision invalidating U.S. Patent No. 6,936,277 for obviousness, based on prior art references. This ruling was critical in enabling the early entry of generic competitors.
• Exclusivity Periods:
  • Orphan Drug Exclusivity: Ampyra received Orphan Drug Designation, which can grant seven years of market exclusivity from the date of approval for a rare disease indication. However, this exclusivity applies to the specific indication and drug.
  • Patent Term Extension: Acorda pursued Patent Term Extensions for its key patents, but these were insufficient to prevent generic entry following successful invalidation challenges.

Regulatory Landscape:

• FDA Approval Process: Ampyra's approval was based on its ability to improve walking speed in MS patients. The regulatory pathway for generics involves demonstrating bioequivalence to the branded product.
• ANDA Filings: Generic manufacturers filed Abbreviated New Drug Applications (ANDAs) with the FDA, which do not require full clinical trials but must prove equivalence.
• ANDA Approval Timeline: Once patents were invalidated or expired, the FDA could approve ANDAs for generic dalfampridine. The first generic approvals began in late 2018 and early 2019.

What is the competitive landscape for Ampyra and dalfampridine?

The competitive landscape for dalfampridine is now dominated by generic manufacturers, significantly impacting Ampyra's market share.

Key Competitors (Generic Manufacturers):

• Teva Pharmaceuticals: One of the largest generic drug manufacturers globally, Teva was among the first to launch its generic dalfampridine product.
• Viatris (formerly Mylan): Another major player in the generics market, Viatris also offers a generic version of dalfampridine.
• Accord Healthcare: A significant European pharmaceutical company with a presence in the U.S. generics market, Accord also manufactures dalfampridine.
• Other Generic Entrants: Several other generic pharmaceutical companies have entered the market, increasing competition.

Competitive Factors:

• Price: This is the primary competitive differentiator in the generic dalfampridine market. Manufacturers compete on cost to gain market share.
• Availability and Distribution: Broad availability through major pharmacy channels and robust distribution networks are crucial.
• Bioequivalence: All approved generic products must meet FDA standards for bioequivalence, ensuring they perform similarly to the branded drug.
• Therapeutic Class: While Ampyra is specific to improving walking in MS, it competes indirectly with other MS therapies that manage different symptoms or disease progression. However, for the specific indication of walking impairment, generic dalfampridine is the direct competitor.

Market Share Shift:

• Pre-Generic Era: Ampyra held nearly 100% of the dalfampridine market.
• Post-Generic Era (2019-Present): Branded Ampyra's market share has fallen below 10%, with generic dalfampridine commanding over 90% of the prescription volume.

What are the future market projections and opportunities for dalfampridine?

The future market for dalfampridine is expected to remain stable, driven by its established efficacy and the cost advantages of generic versions.

Market Projections:

• Sustained Generic Demand: The demand for dalfampridine is projected to remain consistent as it is a well-established treatment for a specific symptom in MS.
• Price Stability (at Lower Levels): While prices may see minor fluctuations due to competitive pressures, significant price increases are unlikely. The market will continue to operate at a significantly lower price point than the branded era.
• Limited Innovation in Dalfampridine: Significant R&D investment into novel dalfampridine formulations or new indications is unlikely, given the mature nature of the molecule and the established generic competition.

Opportunities:

• Emerging Markets: For generic manufacturers, opportunities exist in expanding access to dalfampridine in emerging markets where healthcare infrastructure and affordability are key considerations.
• Lifecycle Management (Limited): While unlikely for dalfampridine itself, companies might explore combination therapies or novel delivery mechanisms for related compounds in MS, though this is speculative.
• Supply Chain Efficiency: Generic manufacturers can focus on optimizing their manufacturing and supply chain processes to maintain cost competitiveness and ensure consistent availability.
• Biosimilar Competition (Not Applicable): Dalfampridine is a small molecule drug, so biosimilar competition is not relevant. However, the concept of broader generic competition for complex biologics serves as a parallel for small molecule market dynamics.

Challenges:

• Continued Price Erosion: The highly competitive generic market may lead to further, albeit small, price erosion.
• Regulatory Scrutiny: Generic drug manufacturers face ongoing regulatory scrutiny regarding manufacturing quality and compliance.
• Competition from Alternative Therapies: While dalfampridine targets a specific symptom, advancements in disease-modifying therapies for MS could indirectly impact the overall patient population seeking symptomatic relief.

Key Takeaways

• Ampyra's market journey exemplifies the impact of patent expirations and generic competition on pharmaceutical revenue streams, with a sharp decline from peak sales to minimal brand presence.
• Generic dalfampridine has captured over 90% of the market share, driven by significant price reductions and broad accessibility.
• Patent litigation, particularly the invalidation of key patents in 2018, was the primary catalyst for generic entry and subsequent market transformation.
• The financial trajectory shows peak brand revenues exceeding $500 million annually, contrasted with vastly reduced revenues for the branded product post-competition.
• Future market projections indicate sustained demand for generic dalfampridine, with continued price competition and limited opportunities for significant innovation in the molecule itself.

Frequently Asked Questions

1. What is the primary indication for Ampyra (dalfampridine)? Ampyra is approved to improve walking in adults with multiple sclerosis (MS).
2. When did generic versions of Ampyra become available? Generic versions of dalfampridine began entering the U.S. market in late 2018 and early 2019, following successful patent challenges.
3. How has the price of dalfampridine changed since the introduction of generics? The price of generic dalfampridine is significantly lower than the brand-name Ampyra, with estimated reductions of 70-90% compared to peak brand pricing.
4. Which companies are currently major manufacturers of generic dalfampridine? Major manufacturers include Teva Pharmaceuticals, Viatris, and Accord Healthcare, among other generic pharmaceutical companies.
5. What is the current market share of branded Ampyra compared to generic dalfampridine? Branded Ampyra holds a minimal market share, while generic dalfampridine accounts for over 90% of the dalfampridine prescription volume.

Citations

[1] Acorda Therapeutics. (2017). 2016 Annual Report. U.S. Securities and Exchange Commission. [2] Acorda Therapeutics. (2023). 2022 Annual Report. U.S. Securities and Exchange Commission.